Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks

Pfizer (PFE) has initiated a review with the European Medicines Agency (EMA) for its Lyme disease vaccine, according to the company. This development could impact investors' views on Pfizer's pipeline and potential market opportunities in Lyme disease prevention.

The FDA authorized Roche and Eli Lilly's Elecsys Phospho-Tau (217P) Plasma test for Alzheimer’s detection via blood draw. The test measures p-tau217, a biomarker linked to Alzheimer’s, and is designed for use in primary-care and specialized settings. Labcorp and Quest Diagnostics plan to offer the test, potentially expanding access. The test is not a standalone diagnosis but part of a broader clinical evaluation. Roche reports 4,500 cobas analyzers are installed in U.S. labs, enabling broad depl

Eli Lilly (LLY) shares rose 1.3% to $1,262.60 after its weight-loss drug, Foundayo, launched in the UK. The company reported a 48% revenue increase in Q2, raising its full-year forecast to $85B-$87B. Lilly aims to secure broader access through the UK's National Health Service, competing with Novo Nordisk's oral Wegovy.

Eli Lilly (LLY) reported 48% Q2 revenue growth, raising guidance, while Novo Nordisk (NVO) saw 7% growth at constant rates, with falling margins. Lilly's Mounjaro and Zepbound drove sales, while Novo's Wegovy showed strong prescription numbers. Lilly is expanding with new drugs, while Novo cut prices and jobs. Investors weigh Lilly's growth vs. Novo's turnaround potential.

Eli Lilly's oral GLP-1 treatment, orforglipron (Foundayo), has been approved in the UK for weight management and type 2 diabetes. A pharmacist warns of potential counterfeit risks due to the tablet's familiarity, advising patients to verify prescribers and pharmacies. The MHRA seized £45m in illegal medicines in 2025, with fake GLP-1 drugs often containing incorrect dosages or harmful contaminants. Patients are urged to check for red flags like social media sales, no clinical consultation, and u

FDA reports over 1,700 adverse events linked to compounded semaglutide and tirzepatide. MEDVi, a company in the compounded GLP-1 market, faced FDA warnings and legal challenges. Novo Nordisk and Lilly have sued over patent infringement. The industry faces regulatory scrutiny and potential legislative changes.